| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.01▲ | 3.98▲ | 3.98▲ | 4.06▼ | 3.82▲ |
| MA10 | 4.00▲ | 3.98▲ | 3.98▲ | 4.08▼ | 3.25▲ |
| MA20 | 3.99▲ | 3.99▲ | 4.02▼ | 3.80▲ | 3.11▲ |
| MA50 | 3.99▲ | 4.10▼ | 4.15▼ | 3.00▲ | 3.75▲ |
| MA100 | 3.99▲ | 4.15▼ | 3.93▲ | 3.08▲ | 4.71▼ |
| MA200 | 4.07▼ | 3.89▲ | 3.38▲ | 3.57▲ | 5.58▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.004▲ | 0.010▲ | 0.002▲ | -0.020▼ | 0.214▲ |
| RSI | 56.052▲ | 50.462▲ | 46.488▼ | 64.151▲ | 60.226▲ |
| STOCH | 54.545 | 44.046 | 37.222 | 60.270 | 87.295▲ |
| WILL %R | -36.364 | -28.571 | -33.333 | -38.144 | -15.102▲ |
| CCI | 77.778 | 90.505 | 38.108 | 17.639 | 120.546▲ |
|
Thursday, June 12, 2025 05:21 AM
Key Insights Institutions' substantial holdings in scPharmaceuticals implies that they have significant influence ...
|
|
Thursday, May 22, 2025 05:29 AM
Shares of scPharmaceuticals (NASDAQ:SCPH) have lost 37% of their value over the past three years and are down 11% so far in 2025. Interestingly, Furoscix was approved in October 2022 with share ...
|
|
Friday, May 16, 2025 05:30 AM
scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Good afternoon and welcome to scPharmaceuticals First Quarter 2025 Earnings Conference Call.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 16/06/25 | 4.06 | 4.06 | 3.975 | 4.02 | 131,186 |
| 13/06/25 | 3.92 | 4.06 | 3.8595 | 3.95 | 211,100 |
| 12/06/25 | 4.06 | 4.185 | 3.97 | 4.00 | 218,163 |
| 11/06/25 | 4.29 | 4.37 | 4.05 | 4.08 | 308,182 |
| 10/06/25 | 4.21 | 4.39 | 4.175 | 4.27 | 213,140 |
| 09/06/25 | 4.27 | 4.29 | 4.16 | 4.25 | 189,838 |
| 06/06/25 | 4.17 | 4.36 | 4.0827 | 4.20 | 424,761 |
| 05/06/25 | 4.12 | 4.29 | 4.06 | 4.11 | 631,765 |
| 04/06/25 | 3.85 | 4.15 | 3.83 | 4.12 | 362,263 |
| 03/06/25 | 3.79 | 3.98 | 3.755 | 3.85 | 288,769 |
|
|
||||
|
|
||||
|
|